Singapore markets close in 2 hours 36 minutes
Straits Times Index
3,307.53 +10.64 (+0.32%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,448.25 +241.12 (+1.32%) FTSE 100
8,172.15 +50.91 (+0.63%) Bitcoin USD
59,417.55 +1,897.91 (+3.30%) CMC Crypto 200
1,298.23 +21.25 (+1.66%)
Halozyme Therapeutics, Inc. (HALO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 39.30 |
| Open | 39.56 |
| Bid | 39.80 x 200 |
| Ask | 39.87 x 200 |
| Day's range | 38.88 - 40.41 |
| 52-week range | 29.85 - 45.00 |
| Volume | |
| Avg. volume | 1,005,014 |
| Market cap | 5.059B |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | 18.96 |
| EPS (TTM) | 2.10 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 51.11 |
ZacksHalozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireMahesh Krishnan Elected to Halozyme's Board of Directors
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
ZacksWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
© 2024 Yahoo. All rights reserved.